MindWalk (NASDAQ:HYFT) Issues Quarterly Earnings Results

MindWalk (NASDAQ:HYFT) issued its earnings results on Wednesday. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01), FiscalAI reports. The business had revenue of $3.03 million during the quarter. MindWalk had a negative return on equity of 69.37% and a negative net margin of 66.79%.

MindWalk Stock Performance

Shares of HYFT stock opened at $1.44 on Thursday. The business’s 50 day simple moving average is $1.56. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.64. The company has a market cap of $67.26 million, a price-to-earnings ratio of -7.20 and a beta of 0.83. MindWalk has a 52-week low of $0.99 and a 52-week high of $3.25.

Hedge Funds Weigh In On MindWalk

Several institutional investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in MindWalk during the 4th quarter valued at about $51,000. Bridgeway Capital Management LLC bought a new position in shares of MindWalk during the 4th quarter worth approximately $91,000. Bank of Montreal Can grew its holdings in MindWalk by 81.0% in the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after purchasing an additional 24,500 shares during the last quarter. XTX Topco Ltd increased its holdings in shares of MindWalk by 118.6% during the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after acquiring an additional 44,331 shares in the last quarter. Finally, Jane Street Group LLC increased its stake in MindWalk by 147.3% during the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock valued at $293,000 after purchasing an additional 96,018 shares in the last quarter. Hedge funds and other institutional investors own 6.70% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on HYFT shares. Weiss Ratings restated a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. HC Wainwright reissued a “buy” rating on shares of MindWalk in a report on Monday. Finally, JonesTrading assumed coverage on shares of MindWalk in a research note on Thursday, April 16th. They set a “buy” rating and a $5.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.